The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.
about
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesSynthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenesSigns of deferasirox genotoxicityLow oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.Targeting cancer by binding iron: Dissecting cellular signaling pathwaysDeferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.Iron deprivation in cancer--potential therapeutic implicationsEffects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.Iron metabolism: current facts and future directions.The role of iron in tumour cell proliferation.Iron chelation in the treatment of cancer: a new role for deferasirox?Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments.Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.Effects of oral iron chelator deferasirox on human malignant lymphoma cells.Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
P2860
Q28388335-DEB528EC-3F7D-4024-9AD7-350C2E259692Q30615373-BDC5AA6C-C7E5-4DA5-9B9F-78477623B4E5Q33849491-1E617704-DD89-4097-A14C-982A0E674494Q35911202-D30A9569-E37C-49F4-B248-1CC894AB93D2Q36326247-CE10483C-CFB4-4CB1-916A-B612683107F5Q36681744-9FD43886-AC9E-4D6F-B68E-13EAEC183B31Q37177365-D71E5039-0D41-473C-9215-22C20ACE9ECDQ37373290-9B16C174-5946-40E6-BC7D-3C4C42D80E1FQ37508402-8B25F5CB-D79B-472A-BA13-10FB7496209EQ37842957-DB7EF72E-F523-465E-95BD-967BB0382C7CQ38112400-4629DEEC-0EF0-4123-A200-35D0385AAD8AQ38982079-8B0B3B9B-ADED-49BE-A368-6D63A6C30D27Q39269756-BAE70C55-0BD9-414A-ACED-BF7017FCE5AAQ39870984-6E34B216-A0B8-4E05-A9B9-388F647EBEA3Q41494907-021A4DD4-5F60-48F3-B049-9EDB6DAE0A04Q42233318-72D73096-A110-473B-967C-8100792579C5Q46345511-604A6EDF-2777-41C0-BF41-442D87860FB7Q53216728-27E72A94-E896-4CF8-8D15-3AD96EBA616F
P2860
The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The new orally active iron che ...... ocyte cultures than O-trensox.
@en
type
label
The new orally active iron che ...... ocyte cultures than O-trensox.
@en
prefLabel
The new orally active iron che ...... ocyte cultures than O-trensox.
@en
P2093
P1476
The new orally active iron che ...... ocyte cultures than O-trensox.
@en
P2093
François Gaboriau
Gérard Lescoat
Hanspeter Nick
Jean-Louis Pierre
Karine Chantrel-Groussard
Nicole Pasdeloup
Pierre Brissot
René Havouis
P304
P356
10.1016/J.EJPHAR.2006.05.001
P407
P577
2006-05-11T00:00:00Z